Background {#Sec1}
==========

Alzheimer's disease (AD) is the most common type of dementia in persons aged 65 years and older \[[@CR1], [@CR2]\]. Pathologically, it is characterized primarily by the appearance of both neuritic plaques (NPs) containing oligomers of β-amyloid and neurofibrillary tangles (NFTs), accompanied by a progressive loss of neurons in the brain \[[@CR3], [@CR4]\]. Also, cerebral amyloid angiopathy (CAA), which is caused by aggregates of β-amyloid in walls of blood vessels in the brain, is found in as many as 90% of autopsy-confirmed AD cases \[[@CR5]\]. Previously, *Beecham et al.* identified multiple significant gene associations in a genome-wide association study (GWAS) for several AD-related neuropathological traits, including NP, NFT, and CAA measured in brains from subjects with pathologically confirmed AD cases and from control subjects with no evidence of neurological disease \[[@CR6]\]. We hypothesized that additional novel associations could be identified in models allowing a genetic variant to influence more than one trait (i.e., pleiotropy). In this study, we performed genome-wide pleiotropy analyses of joint models of NP, NFT, and CAA using summary data from the previous study \[[@CR6]\].

Methods {#Sec2}
=======

Study population, neuropathological trait selection, and data processing {#Sec3}
------------------------------------------------------------------------

We obtained summary statistics from univariate GWAS of NP, NFT, and CAA \[[@CR6]\]. These results were derived from meta-analyses of 12 studies including 3598 subjects (3135 AD cases, 463 controls) of European ancestry. Neuropathological data for the entire sample were reviewed and harmonized by one neuropathologist for consistency across studies \[[@CR6]\]. Although *Beecham et al.* \[[@CR6]\] also evaluated Lewy body disease, hippocampal sclerosis, and vascular brain disease, we limited our present analyses to neuropathological outcomes most directly linked to AD and moderately correlated with each other (i.e., NP, NFT, and CAA). Uncorrelated traits are unlikely to show significant pleiotropic associations, and results from pleiotropy analysis will be similar to those from univariate models (i.e., single phenotype) if the traits are highly correlated. Details of subject recruitment, genotyping, genotype imputation, quality control procedures, population substructure analysis, and statistical methods for association analyses of individual traits were reported previously \[[@CR6], [@CR7]\]. Sample demography of the 3598 subjects with autopsied brains and genotypes (3135 cases and 463 controls) is described in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Univariate genome-wide association analyses {#Sec4}
-------------------------------------------

Results from the association tests by *Beecham et al*. \[[@CR6]\] in each dataset for each neuropathologic trait with genotypes imputed using the 1000 Genomes Project reference panel (GRCh37 at December 2010) for a genome-wide set of single-nucleotide polymorphisms (SNPs) were obtained using ordinal logistic regression models including the first three principal components of ancestry as covariates to account for population substructure \[[@CR6]\]. NP and NFT measures were analyzed in well-established ordinal rankings (NPs: none, sparse, moderate, and frequent by Consortium to Establish a Registry for Alzheimer's Disease \["CERAD"\] scoring \[[@CR8]\]; NFT: none, transentorhinal, limbic, and isocortical by Braak and Braak staging \[[@CR9]\]), and CAA was analyzed as a binary trait (present or absent). Full details of these analyses are reported elsewhere \[[@CR6]\]. We used GWAS meta-analysis summary statistics (β and SE) of the three neuropathologic traits for 6.5 million imputed SNPs after omitting SNPs from studies if the minor allele frequency was ≤ 1%, imputation quality (*R*^2^) was ≤ 0.4, or dosage variance was ≤ 0.02.

Genome-wide pleiotropy analyses {#Sec5}
-------------------------------

We conducted a genome-wide pleiotropy analysis for each pair of the three neuropathological traits using the O'Brien method \[[@CR10], [@CR11]\], which is implemented in an R library ("CUMP") \[[@CR12]\]. This method combines univariate test statistics (Z-scores from β and SE values) of all SNPs from separate GWASs for individual phenotypes to compute a test statistic that follows a multivariate normal distribution. The covariance matrix of the distribution was approximated by the sample covariance matrix of the test statistics of all SNPs. Under the null hypothesis, an SNP is not associated with any of the phenotypes. The alternative hypothesis is that an SNP is associated with at least one of the phenotypes. We defined a SNP as having a pleiotropic effect on two phenotypes when the *P* value for the O'Brien test statistic from the joint model of association of two phenotypes (*P*~joint~) with the SNP is at least one order of magnitude more significant than the *P* values (*P*~univariate~) for both phenotypes and the univariate *P* values are at least nominally significant (*P*~univariate~ \< 0.05). As a supplementary analysis, we also conducted a trivariate pleiotropy genome-wide analysis for the three neuropathological traits. The genome-wide significance (GWS) threshold for these analyses was set at *P* \< 5.0 × 10^−8^.

Gene-based association {#Sec6}
----------------------

We performed genome-wide gene-based tests for each joint model using results from individual SNP tests. SNPs within 30 kb of the transcription start and end sites were included in each gene-based test. These analyses were carried out using the versatile gene-based test ("VEGAS") method \[[@CR13]\], which computes an empirical *P* value through Monte Carlo simulations based on linkage disequilibrium patterns of the European ancestry population in the 1000 Genomes Project (GRCh37 released March 2012). The GWS level for the gene-based tests was set at 2.7 × 10^−6^, which was calculated as the nominal significance level 0.05 divided by the total number of genes tested (*n* = 18,500).

Expression quantitative trait locus analysis {#Sec7}
--------------------------------------------

The association of SNP genotypes with gene-level expression (i.e., expression quantitative trait loci \[eQTLs\]) was evaluated using version 6 of the GTEx Portal database (<http://www.gtexportal.org>/; \[[@CR14]\]) and data from the Mayo Clinic brain expression GWAS (eGWAS) (<https://www.synapse.org/#!Synapse:syn3157249> or <http://alois.med.upenn.edu/niagads>; \[[@CR15]\]). The GTEx Portal provides eQTL association summary statistics (β and *P* values) across 43 different tissues from 175 subjects. The Mayo Clinic brain eGWAS data were generated from the cerebellum (CER; 197 AD and 177 non-AD control subjects) and temporal cortex (TCX; 202 AD and 197 non-AD control subjects) regions. Gene expression measures for 24,526 probes were generated with the Illumina Whole Genome DASL array (Illumina, San Diego, CA, USA). SNP genotype data for the Mayo Clinic eGWAS were obtained from the Mayo Clinic late-onset AD GWAS \[[@CR16]\]. AD cases were diagnosed as definite AD according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria, whereas non-AD controls had other neuropathologies. For each brain region, association of gene expression and imputed SNP genotype (GRCh36) was evaluated using linear regression, including covariates for AD status, apolipoprotein E (*APOE)* ε4 dosage (0, 1, or 2), age at death, sex, plate, RNA integrity number (RIN), and adjusted RIN (RIN − RINmean^2^). Analyses were also conducted for AD cases and controls separately.

Differential gene expression analysis {#Sec8}
-------------------------------------

Differential gene expression (DGE) analysis was performed using publicly available brain whole-transcriptome RNA-sequencing (RNA-Seq) data \[[@CR17]\] and microarray data (Gene Expression Omnibus accession number \[GEO:GSE44772\] \[[@CR18]\]). The RNA-Seq data include DGE summary statistics for the CER and TCX derived from 86 patients with AD and 80 control subjects (<https://www.synapse.org>). Following a quality control step, 80 AD and 76 control brains were analyzed. All subjects underwent RNA-Seq using the Illumina HiSeq 2000 sequencing system (101 bp, paired-end sequencing) at the Mayo Clinic Genomic Core Facility. All AD and some of the control brains were from the Mayo Clinic Brain Bank, whereas other control brains were from the Banner Sun Health Research Institute (Sun City, AZ, USA). Following quality control, raw read counts normalized according to conditional quantile normalization (CQN) employing the Bioconductor package were used in the analyses. For DGE comparing AD with controls, multivariable linear regression analyses were conducted in R, using CQN normalized gene expression measures and including age at death, sex, RIN, brain tissue source, and flow cell as biological and technical covariates. To account for any CNS cell-population changes that occur as a consequence of disease pathology, we also included cell-specific gene levels as covariates, using the expression levels for the five central nervous system (CNS)-specific genes as follows: *ENO2* for neurons \[ENCODE:ENSG00000111674\], *GFAP* for astrocytes \[ENCODE:ENSG00000131095\], *CD68* for microglia \[ENCODE:ENSG00000129226\], *OLIG2* for oligodendrocytes \[ENCODE:ENSG00000205927\], and *CD34* for endothelial cells \[ENCODE:ENSG00000174059\].

The microarray gene expression data were generated from autopsied brains collected from dorsolateral prefrontal cortex (DLPFC), visual cortex (VCX), and CER regions of 129 AD patients and 101 control subjects. Samples were profiled on a custom-made Agilent 44K array (Agilent Technologies, Santa Clara, CA, USA) containing 40,638 human genes. Gene expression data were normalized using Rosetta Resolver gene expression analysis software as previously described \[[@CR18]\]. The association between expression of each gene (outcome) and AD status (predictor) was tested using linear regression adjusting for RIN, postmortem interval, batch, preservation method, pH in tissues, age, sex, and the five cell-type markers.

Results {#Sec9}
=======

NP, NFT, and CAA were moderately correlated (NP-NFT, *r* = 0.68; NP-CAA, *r* = 0.56; NFT-CAA, *r* = 0.40; *P* \< 2.2 × 10^−16^ for each pair of traits), indicating a potential for discovery of novel associations in pleiotropy analysis.

Bivariate GWAS results {#Sec10}
----------------------

There was no inflation in *P* values for the GWAS of the three neuropathological traits analyzed individually (genomic control parameter, λ = 1.00, 1.01, and 0.96 for NP, NFT, and CAA, respectively) or as joint outcomes (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Results of the pleiotropy GWAS are shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S2. As reported previously, with the exception of *APOE*, only 15 of 25 previously known AD loci attained at least a nominal association with NP, NFT, or CAA \[[@CR6]\]. Three of the previously established AD loci---*BIN1*, *HLA* region, and *PICALM*---were moderately associated (*P* \< 10^−4^) in the pleiotropy analysis for NP and NFT at a significance level of at least one order of magnitude smaller compared with the results from univariate analyses (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Two novel GWS associations were detected in the pleiotropy analyses (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). rs34487851, an SNP located approximately 40 kb upstream of *C2orf40*, was associated with the joint model of NP and NFT (*P*~joint~ = 2.0 × 10^−8^). An intronic SNP in *HDAC9*, rs79524815, was associated with the joint model of NFT and CAA (*P*~joint~ = 1.1 × 10^−8^). The major allele *A* of rs34487851 and the minor allele *G* of rs79524815 are associated with increased NP and NFT and with increased NFT and the presence of CAA, respectively. Both of these findings were at least one order of magnitude more significant than for the univariate traits (Table [1](#Tab1){ref-type="table"}) and were supported by evidence from multiple SNPs at those locations (Fig. [1](#Fig1){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Table S3).Table 1Genome-wide significant association (*P* \< 5.0 × 10^−8^) of novel genes in the genome-wide pleiotropy analyses (joint models) of the three neuropathological traits neuritic plaque, neurofibrillary tangles, and cerebral amyloid angiopathyUnivariate modelsJoint modelsAD statusNPNFTCAANP + NFTNP + CAANFT + CAAChromosomeSNPGeneEARAEAFβ value (SE)*P* valueβ value (SE)*P* valueβ value (SE)*P* valueβ value (SE)*P* valueDirection*P* valueDirection*P* valueDirection*P* value2rs34487851*ECRG4* ^a^GA0.27−0.42 (0.09)5.8 × 10^−6^−0.3 (0.06)7.7 × 10^−7^−0.25 (0.06)4.5 × 10^−6^−0.14 (0.08)0.06−2.0 × 10^−8^−2.5 × 10^−6^−2.1 × 10^−5^7rs79524815*HDAC9*GT0.030.69 (0.31)0.030.43 (0.19)0.030.79 (0.19)2.3 × 10^−5^1.16 (0.26)9.1 × 10^−6^+1.3 × 10^−4^+3.3 × 10^−6^+1.1 × 10^−8^*Abbreviations: EA* Effect allele, *RA* Reference allele, *EAF* Effect allele frequency, *SNP* Single-nucleotide polymorphism, *AD* Alzheimer's disease, *NP* Neuritic plaque, *NFT* Neurofibrillary tangles, *CAA* Cerebral amyloid angiopathy^**a**^Also known as *C2orf40*Fig. 1Regional association plots of (**a**) *C2orf40* from the joint model of neuritic plaque (NP) and neurofibrillary tangles (NFT) and (**b**) *HDAC9* from the joint model of NFT and cerebral amyloid angiopathy (CAA)

Bivariate gene-based pleiotropy analysis results {#Sec11}
------------------------------------------------

Three contiguous novel genes on chromosome 2p25.3 (*TRAPPC12*, *TRAPPC12-AS1*, and *ADI1*) were associated with the joint model of NFT and CAA at a gene-wide significant level (*P* ≤ 2.0 × 10^−6^) (Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3). Of note, one SNP in this region (rs35067331 in *TRAPPC12*) was associated with the NFT-CAA outcome at nearly the GWS level (*P*~joint~ = 5.8 × 10^−8^) (Additional file [1](#MOESM1){ref-type="media"}: Table S4).Table 2Gene-wide significant results (*P* \< 2.7 × 10^−6^) from gene-based tests of pleiotropy single-nucleotide polymorphism association resultsUnivariate gene-based testsPleiotropy gene-based testsChromosomeStartEndGeneNPNFTCAANP + NFTNP + CAANFT + CAA23,383,4463,483,342*TRAPPC12*0.094.0 × 10^−5^0.50.010.072.0 × 10^−6^23,485,0133,486,180*TRAPPC12-AS1*0.0023.9 × 10^−5^5.0 × 10^−3^1.6 × 10^−5^2.1 × 10^−5^\< 1.0 × 10^−6^23,501,6903,523,350*ADI1*0.0031.6 × 10^−5^7.0 × 10^−4^3.2 × 10^−5^4.0 × 10^−6^\< 1.0 × 10^−6^*Abbreviations: NP* Neuritic plaque, *NFT* Neurofibrillary tangles, *CAA* Cerebral amyloid angiopathyGene-based *P* values were computed through 1 million permutations, so the smallest *P* value is 1.0 × 10^−6^

Trivariate GWAS and gene-based pleiotropy analysis results {#Sec12}
----------------------------------------------------------

We conducted trivariate GWAS and gene-based association analyses to identify genetic factors common to NP, NFT, and CAA. There was no evidence for genomic inflation (λ = 0.99) in the results from the trivariate model (Additional file [1](#MOESM1){ref-type="media"}: Figure S4). GWS association was observed only for *APOE* isoform SNP rs429358 (*P* = 2.1 × 10^−47^), whereas associations at *C2orf40*, *HDAC9*, and *TRAPPC12* were attenuated (Additional file [1](#MOESM1){ref-type="media"}: Table S5).

eQTL analysis {#Sec13}
-------------

We performed eQTL association analysis to examine whether the expression levels of the five GWS significant genes identified in the pleiotropy association tests differed between carriers and noncarriers of the risk alleles from those loci. Because information about the two GWS SNPs was not available in the GTEx Portal database or in the Mayo Clinic brain eGWAS, we analyzed proxy SNPs that are in high linkage disequilibrium (LD; *D′* ≥ 80) with the GWS SNPs. According to GTEx, rs34487851 proxy SNP rs1232803 is a *cis*-acting eQTL, and the major allele *A*, which is associated with higher NP and NFT, is also significantly associated with decreased expression of *C2orf40* in several tissues, including the esophagus (*P* = 3.5 × 10^−5^), transverse colon (*P* = 4.7 × 10^−4^), and tibial artery (*P* = 1.7 × 10^−3^), but not in any brain regions. In the Mayo Clinic brain eGWAS, proxy SNPs for rs34487851 were not *cis*-acting eQTLs for *C2orf40*. In GTEx, proxy SNPs for rs79524815 were not associated with the expression of *HDAC9*. However, in the brain eGWAS, the minor alleles of proxy SNPs for rs79524815, which are associated with higher NFT and CAA, were significantly associated with lower *HDAC9* levels in the CER (probe ID: ILMN_1803563; best eQTL, rs4721721; *P* = 0.003) but not in the TCX (Additional file [1](#MOESM1){ref-type="media"}: Table S3). According to GTEx, rs35067331 is a *cis*-acting eQTL, and its major allele *C*, which is associated with higher NFT and CAA, is significantly associated with increased expression of *TRAPPC12-AS1* in several brain regions (best *P* = 2.1 × 10^−7^ in cortex) and *ADI1* (*P* = 0.03) in the caudate nucleus, but not with differential expression of *TRAPPC12* in any brain regions (Additional file [1](#MOESM1){ref-type="media"}: Table S4). In the Mayo Clinic brain eGWAS data, rs35067331 and its proxy SNPs were not *cis*-acting eQTLs for *ADI1* or *TRAPPC12*. Unfortunately, information about *TRAPPC12-AS1* was unavailable in the brain eGWAS.

Differential gene expression analysis {#Sec14}
-------------------------------------

We investigated whether the expression levels of *C2orf40*, *HDAC9*, and *TRAPPC12*/*TRAPPC12-AS1*/*ADI1* differed in AD brains compared with non-AD control brains in the publicly available RNS-Seq and microarray datasets (Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). There were no significant differences in *C2orf40* expression between subjects with AD and control subjects in the TCX or CER in the Mayo Clinic RNA-Seq DGE profiling. However, *C2orf40* was significantly downregulated in subjects with AD compared with control subjects in the CER (*P* = 1.6 × 10^−3^), DLPFC (*P* = 0.04), and VCX (*P* = 2.7 × 10^−3^) in the microarray brain expression data. *HDAC9* was significantly downregulated in subjects with AD compared with control subjects in several brain regions, including the TCX (*P* = 1.5 × 10^−4^) and CER (*P* = 0.04) in the RNA-Seq profiling data and in the DLPFC (*P* = 7.9 × 10^−3^) and VCX (*P* = 5.6 × 10^−4^) in the microarray expression data. *ADI1* expression was downregulated in subjects with AD in the CER in the microarray data (*P* = 4.9 × 10^−4^). The RNA-Seq DGE profiling indicated that *TRAPPC12-AS1* expression was significantly increased in subjects with AD in the TCX (*P* = 1.3 × 10^−3^). In contrast, expression of *TRAPPC12* was significantly lower in subjects with AD than in control subjects in the TCX (*P* = 0.01) in the RNA-Seq and in the CER (*P* = 1.1 × 10^−3^) and VCX (*P* = 3.2 × 10^−4^) in the microarray data. Information about expression of *TRAPPC12-AS1* was not available in the microarray data. The majority of these nominally significant findings survived correction for multiple testing (*P* \< 2.27 × 10^−3^).Table 3Results of differential gene expression analysis in brainRNA-SeqMicroarrayCERTCXCERDLPFCVCXGeneβ value (SE)P valueβ value (SE)*P* valueβ value (SE)*P* valueβ value (SE)*P* valueβ value (SE)*P* value*ECRG4* ^a^0.06 (0.20)0.770.19 (0.24)0.43−0.18 (0.05)**1.6 × 10** ^**−3**^−0.12 (0.06)0.04−0.12 (0.04)2.7 × 10^−3^*HDAC9*−0.24 (0.12)0.04−0.31 (0.08)**1.5 × 10** ^**−4**^−0.01 (0.02)0.77−0.09 (0.03)7.9 × 10^−3^−0.06 (0.02)**5.6 × 10** ^**−4**^*TRAPPC12*−0.05 (0.06)0.35−0.13 (0.05)0.01−0.09 (0.03)**1.1 × 10** ^**−3**^−0.03 (0.02)0.09−0.08 (0.02)**3.2 × 10** ^**−4**^*TRAPPC12-AS1*0.22 (0.12)0.060.59 (0.18)**1.3 × 10** ^**−3**^------------*ADI1*−0.10 (0.08)0.19−0.07 (0.08)0.36−0.10 (0.03)**4.9 × 10** ^**−4**^−0.03 (0.03)0.31−0.01 (0.03)0.64*Abbreviations: CER* Cerebellum, *TCX* Temporal cortex, *DLPFC* Dorsolateral prefrontal cortex, *CER* Cerebellum, *TCX* Temporal cortex, *DLPFC* Dorsolateral prefrontal cortex, *VCX* Visual cortexResults were obtained from analyses of RNA-Seq data in the Synapse database (<https://www.synapse.org>; \[[@CR17]\]) and microarray data in the Gene Expression Omnibus database \[GEO:GSE44771\]. Negative β value indicates lower level of gene expression in AD cases compared with controls and vice versa. Results that remained significant after multiple test correction (*P* = 0.05/22 = 2.27 × 10^−3^) are highlighted in **bold**^a^Also known as *C2orf40*Fig. 2Box plots showing differential expression in microarray data \[GEO:GSE44772\] between AD cases and controls for *C2orf40*, *HDAC9*, *TRAPPC12*, and *ADI1* in the cerebellum (CER; left column), dorsolateral prefrontal cortex (DLPFC; middle column), and visual cortex (VCX; right column). AD Alzheimer's disease

To contextualize our findings, we evaluated DGE among AD cases and controls for 26 previously established AD genes (Additional file [1](#MOESM1){ref-type="media"}: Table S6) \[[@CR19]--[@CR21]\]. With notable exceptions of *EPHA1* (*P* = 2.8 × 10^−7^) and *SLC24A4* (*P* = 7.0 × 10^−5^) in CER in the RNA-Seq data and *ABCA7* in DLPFC (*P* = 2.5 × 10^−7^) and VCX (*P* = 4.9 × 10^−7^) in the microarray data, none of the results for the other 23 genes were significant after correcting for 127 tests (*P* \< 3.94 × 10^−4^).

Discussion {#Sec15}
==========

A previous GWAS of neuropathologic traits including NP, NFT, and CAA identified GWS associations with *APOE* only \[[@CR6]\]. Our pleiotropy analysis of all pairwise combinations of these traits identified GWS associations with *APOE* and three regions not previously reported with any neuropathologic traits or AD risk, including *C2orf40* for the joint model comprising NP and NFT, as well as *HDAC9* and *TRAPPC12/TRAPPC12-AS1/ADI1* for the joint model comprising NFT and CAA. Our DGE study found that *HDAC9* is significantly downregulated in several brain regions in subjects with AD compared with control subjects. Moreover, we observed that the *G* allele of *HDAC9* SNP rs79524815 is associated with a higher level of the joint outcome of NFT and CAA, and proxy SNPs for rs79524815 (which are suggestively associated with the joint outcome of NFT and CAA) are associated with decreased *HDAC9* expression in subjects with AD (Additional file [1](#MOESM1){ref-type="media"}: Table S3). The pleiotropy analysis also revealed that 4 (*BIN1*, *HLA*, *PICALM*, and *APOE*) of the 25 previously reported GWS AD risk loci \[[@CR7], [@CR19]--[@CR21]\] were at least one order of magnitude more significantly associated with the joint model of NP + NFT than each of these traits analyzed separately, suggesting that these genes are involved in pathways leading to both plaques and tangles \[[@CR22]--[@CR25]\].

It is notable that pleiotropy analyses for the model including NP, NFT, and CAA did not yield any GWS findings. Moreover, the GWS associations identified in the bivariate models were attenuated in the trivariate model. These results suggest that the mechanisms or pathways underlying the bivariate associations probably do not encompass all three traits, and this conclusion may generalize genome-wide.

*C2orf40*, also known as *esophageal cancer-related gene 4* (*ECRG4*), is a tumor suppressor gene \[[@CR26]\] that encodes a peptide hormone that is involved in NFT formation in transgenic mice \[[@CR27]\], senescence of precursor cells in the CNS during aging \[[@CR28]\], and activation of microglia and peripheral mononuclear leukocytes \[[@CR29]\]. We observed that rs34487851 allele *A* is associated with higher NP and NFT and lower expression of *ERCG4,* albeit not in the brain. We also found that *ERCG4* expression was significantly lower in AD cases than in controls in several brain regions. Abnormal downregulation of *C2orf40* was previously reported in brain injury \[[@CR30]\] as well as in several cancer cell types \[[@CR31], [@CR32]\].

*HDAC9* encodes a member of class IIa histone genes that deacetylate histones, thereby remodeling chromatin structure and controlling gene expression \[[@CR33], [@CR34]\] that has previously been linked to epigenetic mechanisms \[[@CR35]\] and memory loss \[[@CR36]\] in AD and also has been proposed as a possible therapeutic target \[[@CR37]--[@CR39]\]. GWS association of ischemic stroke with an *HDAC9* variant was identified by GWAS \[[@CR40]\]. Structural variants including deletions and copy number variants in *HDAC9* have been identified in patients with schizophrenia and patients with autism \[[@CR41], [@CR42]\]. *MEF2C*, one of the well-established AD risk loci \[[@CR21]\], stimulates *HDAC9* expression, but *HDAC9* suppresses *MEF2C* transcription, resulting in a negative feedback loop \[[@CR43]\]. In a previously reported coexpression network study in AD and control brains, *HDAC9* and *MEF2C* were clustered together in the top fourth module ranked by relevance to AD pathology, and expression of *HDAC9* and *MEF2C* was inversely correlated with Braak stage (*HDAC9*, *r* = −0.71; *MEF2C*, *r* = −0.65) and frontal atrophy (*HDAC9*, *r* = −0.57, *MEF2C*, *r* = −0.51) \[[@CR18]\]. These findings are consistent with our observation that *HDAC9* expression is reduced in subjects with AD and in the subjects with *HDAC9* SNP alleles associated with higher NFT and CAA. Decreased *HDAC9* expression has also been linked to increased neuronal apoptosis \[[@CR44], [@CR45]\]. Collectively, findings from our and other studies indicate that *MEF2C* and *HDAC9* may participate in a pathway leading to NFT formation and brain atrophy.

Gene-based analyses identified significant associations with three adjacent loci---*TRAPPC12*, *TRAPPC12-AS1*, and *ADI1*---in a gene-rich region near the end of the short arm of chromosome 2p. *ADI1*, encoding acireductone dioxygenase 1, is involved in methionine salvage and prostate cancer \[[@CR46]\] and has no known relationship to AD. *TRAPPC12* is a subunit of a trafficking protein particle complex that has a role in vesicle trafficking in endoplasmic reticulum (ER) to Golgi \[[@CR47]\]. *TRAPPC12-AS1* is an antisense (noncoding) RNA that contains a 1168 transcript from *TRAPPC12*. We previously established that regulation of vesicular trafficking in the ER to Golgi by several VPS10 receptor domain receptor genes, including *SORL1,* and by other genes encoding members of the retromer complex is an important pathway leading to AD \[[@CR48]--[@CR50]\]. Of the genes in this region, only *TRAPPC12-AS1* showed a pattern of expression in subjects with AD and control subjects that is consistent with the effect direction of the *TRAPPC12* rs35067331 allele's influence on NFT and CAA. It should be noted that *TRAPPC12* expression was significantly lower in AD cases than in control subjects in the TCX (*P* = 0.01) in the RNA-Seq data and the CER (*P* = 1.1 × 10^−3^) and VCX (*P* = 3.2 × 10^−4^) in the microarray data, which could be due to negative feedback by the antisense *TRAPPC12-AS1* transcript \[[@CR51]\].

Our study has several potential caveats. The GWS associations identified in the pleiotropy analysis have moderate supportive evidence for association from other SNPs under the association peaks, probably because of low LD with the top SNPs. The two GWS SNPs near *C2orf40* and *HDAC9* were not associated with AD risk in one of the largest GWASs for AD (rs34487851, *P* = 0.07; rs79524815, *P* = 0.73) \[[@CR19], [@CR21]\]. However, approximately 87% of the autopsy samples used in this pleiotropy analysis (as well as in the *Beecham et al.* study \[[@CR6]\]) were from patients with AD. This may indicate that our findings are more relevant with neuropathological progression after onset of AD clinical symptoms. Alternatively, because our study was focused on endophenotypes that might be more proximal than disease diagnosis to effects of the genetic variants \[[@CR52], [@CR53]\], our analyses might have more power to detect those novel associations. Finally, to our knowledge, additional large late-onset AD cohorts with neuropathological and genotype data are not currently available for replication of our association findings. Therefore, validation of the role of these loci in AD will likely require experimental evidence.

Conclusions {#Sec16}
===========

Our findings suggest that genome-wide pleiotropy analysis is a useful approach to identifying novel genetic associations with complex diseases and their endophenotypes. Functional studies are needed to determine whether *C2orf40* or *HDAC9* is a plausible therapeutic target.
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================

 {#Sec17}

Additional file 1: Table S1.Sample characteristics. **Table S2.** Association *P* values of Alzheimer disease loci previously established by GWAS in univariate and pleiotropy association tests of neuropathological features. **Table S3.** Association of *cis*-eQTL for *HDAC9* in the Mayo Clinic brain expression genome-wide association study (eGWAS). rs79524815 was not available in the Mayo Clinic brain eGWAS, so proxy SNPs that are in LD (D′ \> 0.90) with rs79524815 were used for the eQTL test with *HDAC9* expression. **Table S4.** Association of expression of SNPs for *TRAPPC12-AS1* and *ADI1* with neuropathological traits and gene expression in the GTEx portal database. **Table S5.** Association results from the trivariate pleiotropy model of neuritic plaque (NP), neurofibrillary tangles (NFT), and cerebral amyloid angiopathy (CAA) for study-wide significant SNPs in the bivariate pleiotropy model. **Table S6.** Results of differential gene expression analysis by brain region among AD cases and controls for AD loci previously established by GWAS in RNA-Seq and microarray analysis. **Figure S1.** Quantile-quantile plots of observed (y-axis) vs. expected (x-axis) P values of all SNPs (black dots) and after excluding SNPs in *APOE* region (blue dots) for the pleiotropy analysis of (**a**) NP and NFT, (**b**) NP and CAA, and (**c**) NFT and CAA using the O'Brien method \[[@CR10]\]. **Figure S2.** Manhattan plots showing genome-wide pleiotropy analyses of (**a**) NP and NFT, (**b**) NP and CAA, and (**c**) NFT and CAA using the O'Brien method \[[@CR10]\]. Red dashed line represents the genome-wide significance threshold of *P* \< 5.0 × 10^−−8^. Loci achieving genome-wide significance are highlighted in red, and known AD genes that attained at least a moderate significance level (*P* \< 10^−−4^) are highlighted in gold. **Figure S3.** Regional association plots of genes, including *TRAPPC12*, *TRAPPC12-AS1*, and *ADI1,* on chromosome 2 from the joint model of NFT and CAA. **Figure S4.** Genome-wide trivariate pleiotropy analysis of NP, NFT, and CAA. (**a**) Quantile-quantile plot. (**b**) Manhattan plot. (DOCX 1028 kb)

**Electronic supplementary material**

The online version of this article (10.1186/s13195-018-0349-z) contains supplementary material, which is available to authorized users.

The authors express appreciation to Dr. Qiong Yang for help with using the R library ('CUMP' package).

***Members of the Alzheimer Disease Genetics Consortium***

Marilyn S. Albert^1^, Roger L. Albin^2−--4^, Liana G. Apostolova^5^, Steven E. Arnold^6^, Sanjay Asthana^7−--9^, Craig S. Atwood^7,9^, Clinton T. Baldwin^10^, Michael M. Barmada^11^, Lisa L. Barnes^12,13^, Thomas G. Beach^14^, James T. Becker^15^, Duane Beekly^16^, David A. Bennett^12^, Eileen H. Bigio^17,18^, Thomas D. Bird^19,20^, Deborah Blacker^21,22^, Bradley F. Boeve^23^, James D. Bowen^24^, Adam Boxer^25^, James R. Burke^26^, Joseph Buxbaum^108^, Nigel J. Cairns^27^, Laura B. Cantwell^28^, Chuanhai Cao^29^, Chris S. Carlson^30^, Cynthia M. Carlsson^8^, Regina M. Carney^31^, Minerva M. Carrasquillo^32^, Steven L. Carroll^33^, Helena C. Chui^34^, David G. Clark^35^, Paul Crane^80^, David H. Cribbs^36^, Elizabeth A. Crocco^31^, Carlos Cruchaga^37^, Charles DeCarli^38^, F. Yesim Demirci^11^, Philip De Jager^109^, Malcolm Dick^39^, Dennis Dickson^32^, Ranjan Duara^40^, Nilufer Ertekin-Taner^32,41^, Kelley M. Faber^42^, Kenneth B. Fallon^33^, Martin R. Farlow^43^, Steven Ferris^44^, Tatiana M. Foroud^42^, Matthew Frosch^110^, Douglas R. Galasko^45^, Marla Gearing^46,47^, Daniel H. Geschwind^48^, Bernardino Ghetti^85^, John Gilbert^70^, Jonathan D. Glass^49^, Alison M. Goate^37^, Neill R. Graff-Radford^32,41^, Robert C. Green^50^, John H. Growdon^51^, Hakon Hakonarson^52^, Ronald L. Hamilton^53^, Kara L. Hamilton-Nelson^70^, John Hardy^111^, Lindy E. Harrell^35^, Elizabeth Head^54^, Lawrence S. Honig^55^, Matthew J. Huentelman^112^, Christine M. Hulette^56^, Bradley Hyman^51^, Gail P. Jarvik^57,58^, Gregory A. Jicha^59^, Lee-Way Jin^60^, Gyungah Jun^10,61,62^, M. Ilyas Kamboh^11,75^, Anna Karydas^25^, John S.K. Kauwe^63^, Jeffrey A. Kaye^64,65^, Ronald Kim^66^, Neil W. Kowall^67,68^, Joel H. Kramer^69^, Patricia Kramer^64^, Walter Kukull^16,113^, Brian W. Kunkle^70^, Frank M. LaFerla^71^, James J. Lah^49^, Eric Larson^80^, James B. Leverenz^72^, Allan I. Levey^49^, Ge Li^73^, Andrew P. Lieberman^74^, Chiao-Feng Lin^28^, Oscar L. Lopez^75^, Kathryn L. Lunetta^61^, Constantine G. Lyketsos^76^, Wendy J. Mack^77^, Daniel C. Marson^35^, Eden R. Martin^17^, Frank Martiniuk^78^, Deborah Mash^107^, Eliezer Masliah^45,79^, Wayne C. McCormick^80^, Susan M. McCurry^81^, Andrew N. McDavid^30^, Ann C. McKee^67,68^, Marsel Mesulam^18,82^, Bruce L. Miller^25^, Carol A. Miller^83^, Joshua W. Miller^60^, John C. Morris^27,84^, Shubhabrata Mukherjee^80^, Jill R. Murrell^42,85^, Amanda J. Myers^31^, Adam C. Naj^114^, John M. Olichney^38^, Vernon S. Pankratz^86^, Joseph E. Parisi^87^, Amanda Partch^28^, Henry L. Paulson^88^, William Perry^70^, Elaine Peskind^73^, Ronald C. Petersen^23^, Aimee Pierce^36^, Wayne W. Poon^39^, Huntington Potter^89^, Joseph F. Quinn^64^, Ashok Raj^29^, Murray Raskind^73^, Eric Reiman^115,116^, Barry Reisberg^44,90^, Christiane Reitz^55,91,92^, John M. Ringman^5^, Erik D. Roberson^35^, Ekaterina Rogaeva^93^, Howard J. Rosen^25^, Roger N. Rosenberg^94^, Mark A. Sager^8^, Mary Sano^95^, Andrew J. Saykin^42,96^, Julie Schneider^12,117^, Lon S. Schneider^34,97^, William W. Seeley^25^, Amanda G. Smith^29^, Joshua A. Sonnen^98^, Salvatore Spina^85^, Peter St George-Hyslop^93,99^, Robert A. Stern^67^, Rudolph E. Tanzi^51^, Tricia A. Thornton-Wells^100^, John Trojanowski^28^, Juan C. Troncoso^101^, Debby W. Tsuang^20,73^, Otto Valladares^28^, Vivianna M. Van Deerlin^28^, Linda J. Van Eldik^102^, Badri N. Vardarajan^55,91,92^, Harry V. Vinters^5,103^, Jean-Paul Vonsattel^118^, Li-San Wang^28^, Sandra Weintraub^18,104^, Kathleen A. Welsh-Bohmer^26,105^, Jennifer Williamson^55^, Sarah Wishnek^70^, Randall L. Woltjer^106^, Clinton B. Wright^107^, Steven Younkin^32^, Chang-En Yu^80^, and Lei Yu^12^

^1^Department of Neurology, Johns Hopkins University, Baltimore, Maryland; ^2^Department of Neurology, University of Michigan, Ann Arbor, Michigan; ^3^Geriatric Research, Education and Clinical Center (GRECC), VA Ann Arbor Healthcare System (VAAAHS), Ann Arbor, Michigan; ^4^Michigan Alzheimer Disease Center, Ann Arbor, Michigan; ^5^Department of Neurology, University of California, Los Angeles, Los Angeles, California; ^6^Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; ^7^Geriatric Research, Education and Clinical Center (GRECC), University of Wisconsin, Madison, Wisconsin; ^8^Department of Medicine, University of Wisconsin, Madison, Wisconsin; ^9^Wisconsin Alzheimer's Institute, Madison, Wisconsin; ^10^Department of Medicine (Biomedical Genetics), Boston University, Boston, Massachusetts; ^11^Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania; ^12^Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois; ^13^Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois; ^14^Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, Arizona; ^15^Departments of Psychiatry, Neurology, and Psychology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; ^16^National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington; ^17^Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; ^18^Cognitive Neurology and Alzheimer's Disease Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; ^19^Department of Neurology, University of Washington, Seattle, Washington; ^20^VA Puget Sound Health Care System/GRECC, Seattle, Washington; ^21^Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; ^22^Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts; ^23^Department of Neurology, Mayo Clinic, Rochester, Minnesota; ^24^Swedish Medical Center, Seattle, Washington; ^25^Department of Neurology, University of California, San Francisco, San Francisco, California; ^26^Department of Medicine, Duke University, Durham, North Carolina; ^27^Department of Pathology and Immunology, Washington University, St. Louis, Missouri; ^28^Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; ^29^USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida; ^30^Fred Hutchinson Cancer Research Center, Seattle, Washington; ^31^Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida; ^32^Department of Neuroscience, Mayo Clinic, Jacksonville, Florida; ^33^Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama; ^34^Department of Neurology, University of Southern California, Los Angeles, Los Angeles, California; ^35^Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama; ^36^Department of Neurology, University of California, Irvine, Irvine, California; ^37^Department of Psychiatry and Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St. Louis, Missouri; ^38^Department of Neurology, University of California, Davis, Sacramento, California; ^39^Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California; ^40^Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida; ^41^Department of Neurology, Mayo Clinic, Jacksonville, Florida; ^42^Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana; ^43^Department of Neurology, Indiana University, Indianapolis, Indiana; ^44^Department of Psychiatry, New York University, New York, New York; ^45^Department of Neurosciences, University of California, San Diego, La Jolla, California; ^46^Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia; ^47^Emory Alzheimer's Disease Center, Emory University, Atlanta, Georgia; ^48^Neurogenetics Program, University of California, Los Angeles, Los Angeles, California; ^49^Department of Neurology, Emory University, Atlanta, Georgia; ^50^Division of Genetics, Department of Medicine and Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; ^51^Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts; ^52^Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; ^53^Department of Pathology (Neuropathology), University of Pittsburgh, Pittsburgh, Pennsylvania; ^54^Sanders-Brown Center on Aging, Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, Kentucky; ^55^Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York; ^56^Department of Pathology, Duke University, Durham, North Carolina; ^57^Department of Genome Sciences, University of Washington, Seattle, Washington; ^58^Department of Medicine (Medical Genetics), University of Washington, Seattle, Washington; ^59^Sanders-Brown Center on Aging, Department Neurology, University of Kentucky, Lexington, Kentucky; ^60^Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, California; ^61^Department of Biostatistics, Boston University, Boston, Massachusetts; ^62^Department of Ophthalmology, Boston University, Boston, Massachusetts; ^63^Department of Biology, Brigham Young University, Provo, Utah; ^64^Department of Neurology, Oregon Health & Science University, Portland, Oregon; ^65^Department of Neurology, Portland Veterans Affairs Medical Center, Portland, Oregon; ^66^Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, California; ^67^Department of Neurology, Boston University, Boston, Massachusetts; ^68^Department of Pathology, Boston University, Boston, Massachusetts; ^69^Department of Neuropsychology, University of California, San Francisco, San Francisco, California; ^70^The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida; ^71^Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California; ^72^Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio; ^73^Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington; ^74^Department of Pathology, University of Michigan, Ann Arbor, Michigan; ^75^University of Pittsburgh Alzheimer's Disease Research Center, Pittsburgh, Pennsylvania; ^76^Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland; ^77^Department of Preventive Medicine, University of Southern California, Los Angeles, California; ^78^Department of Medicine--Pulmonary, New York University School of Medicine, New York, New York; ^79^Department of Pathology, University of California, San Diego, La Jolla, California; ^80^Department of Medicine, University of Washington, Seattle, Washington; ^81^Northwest Research Group on Aging, University of Washington School of Nursing, Seattle, Washington; ^82^Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; ^83^Department of Pathology, University of Southern California, Los Angeles, Los Angeles, California; ^84^Department of Neurology, Washington University, St. Louis, Missouri; ^85^Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana; ^86^Department of Biostatistics, Mayo Clinic, Rochester, Minnesota; ^87^Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; ^88^Michigan Alzheimer's Disease Center, Department of Neurology, University of Michigan, Ann Arbor, Michigan; ^89^Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado; ^90^Alzheimer's Disease Center, New York University, New York, New York; ^91^Gertrude H. Sergievsky Center, Columbia University, New York, New York; ^92^Department of Neurology, Columbia University, New York, New York; ^93^Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada; ^94^Department of Neurology, University of Texas Southwestern, Dallas, Texas; ^95^Department of Psychiatry, Mount Sinai School of Medicine, New York, New York; ^96^Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, Indiana; ^97^Department of Psychiatry, University of Southern California, Los Angeles, California; ^98^Department of Pathology, University of Washington, Seattle, Washington; ^99^Cambridge Institute for Medical Research and Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom; ^100^Center for Human Genetics and Research, Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee; ^101^Department of Pathology, Johns Hopkins University, Baltimore, Maryland; ^102^Sanders-Brown Center on Aging, Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky; ^103^Department of Pathology & Laboratory Medicine, University of California, Los Angeles, Los Angeles, California; ^104^Department of Psychiatry, Northwestern University Feinberg School of Medicine, Chicago, Illinois; ^105^Department of Psychiatry & Behavioral Sciences, Duke University, Durham, North Carolina; ^106^Department of Pathology, Oregon Health & Science University, Portland, Oregon; ^107^Evelyn F. McKnight Brain Institute, Department of Neurology, Miller School of Medicine, University of Miami, Miami, Florida; ^108^Department of Psychiatry, Mount Sinai Hospital, New York, New York; ^109^Department of Neurology and Psychiatry, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts; ^110^C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Charlestown, Massachusetts; ^111^Department of Molecular Neuroscience, University College London, London, United Kingdom; ^112^Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona; ^113^Department of Epidemiology, University of Washington, Seattle, Washington; ^114^Division of Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania; ^115^Arizona Alzheimer's Consortium, Banner Alzheimer's Institute, Phoenix, Arizona; ^116^Department of Psychiatry, University of Arizona, Phoenix, Arizona; ^117^Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, Illinois; ^118^New York Brain Bank, Columbia University, New York, New York.

Funding {#FPar1}
=======

The Alzheimer's Disease Genetics Consortium supported the collection of samples used in this study through National Institute on Aging (NIA) grants U01-AG032984 and RC2AG036528. Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania and funded by NIA grant U24-AG041689-01. This work was also supported by NIA grants R01-AG048927 (to LAF), R01-AG032990 and RF-AG051504 (to NET), and U01-AG046139 (to NET, SGY, TEG, and NDP), as well as by National Institute of Neurological Disorders and Stroke (NINDS) grant R01-NS080820 (to NET). The Brain and Body Donation Program at Sun Health Research Institute (Sun City, AZ, USA) is supported by NINDS grant U24-NS072026 for the National Brain and Tissue Resource for Parkinson's Disease and Related Disorders; NIA grant P30-AG19610 for the Arizona Alzheimer's Disease Core Center; Arizona Department of Health Services contract 211002 for the Arizona Alzheimer's Research Center; Arizona Biomedical Research Commission contracts 4001, 0011, 05-901, and 1001 to the Arizona Parkinson's Disease Consortium; and the Michael J. Fox Foundation for Parkinson's Research.

Availability of data and materials {#FPar2}
==================================

Summarized genome-wide association study results are available from the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (<https://www.niagads.org>/).

JC, GRJ, and LAF wrote the manuscript. JC, XZ, KLL, and GRJ performed the data analysis. MA, XW, TJM, SGY, DWD, TEG, NDP, and NET provided and interpreted gene expression data from Alzheimer's disease cases and controls. YM, GB, and JM provided technical support. RM, JLH, MAPV, GS, and LAF obtained the funding for this study. GRJ and LAF supervised the project. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

This study was approved by the Boston University Institutional Review Board.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests**.**

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
